Delivery Order SPE2DR25D2105-SPE2DR26F5UZA
- Not listed
- The Defense Logistics Agency awarded a $10,892.79 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with an ultimate completion date of November 4, 2025. This non-set-aside contract was competitively awarded and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order valued at $18,061.85 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on November 5, 2025, with completion expected by November 6, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026. The place of...
- The Defense Logistics Agency awarded a $18,669.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $50,518.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 20, 2025, with an ultimate completion date of June 23, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery will be performed at...
- The Defense Logistics Agency awarded a $28,416.82 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award carries no set-aside designation, reflecting the company's proven capability to...
- The Defense Logistics Agency awarded a delivery order valued at $13,037.95 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on October 23, 2025, with completion scheduled for October 24, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a $3,700.62 delivery order by the Defense Logistics Agency on September 17, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count unit dose packages). The contract represents a firm fixed-price, non-competitive set-aside delivery order with an ultimate completion date of September 18, 2025. This award was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $9,334.98 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packages) on October 27, 2025, with completion targeted for October 28, 2025. This is a firm fixed price delivery order with no set-aside designation, issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX). The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $26,705.50 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with a firm fixed price structure. This non-competitive delivery order was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is...
- The Defense Logistics Agency awarded a $9,470.81 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on November 3, 2025, with an ultimate completion date of November 4, 2025. This non-compete award was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement valued through December 2026 that serves as the primary pharmaceutical supply vehicle...
- SPE2DR25D2105Indefinite Delivery Contract
- SPE2DR25D2105-SPE2DR26F5UZADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $40,365.01 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on November 13, 2025, with an ultimate completion date of November 14, 2025. This firm fixed-price, non-set-aside contract was awarded competitively and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This award exemplifies AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical procurement needs, particularly for military and veteran healthcare systems. As a major healthcare solutions provider, the company maintains a comprehensive $999,999,999.00 IDC through December 2026 that enables it to supply a broad spectrum of pharmaceutical products and medical supplies globally. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the Defense Health Agency's need for specialty medications to support military personnel and beneficiaries. AmerisourceBergen's consistent receipt of competitively awarded federal contracts underscores its capability to meet rigorous procurement standards across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $40.4k | 11/13/25 |